论文部分内容阅读
Ｎｏｖａｒｉｔｓ公司胆碱酯酶抑制剂ｒｉｖａｓｔｉｇｍｉｎｅ（Ｅｘｅｌｏｎ）于２０００年６月底在美国上市，从而拓展了阿尔茨海默病治疗药市场，同时与Ｅｉｓａｉ／Ｐｆｉｚｅｒ公司的多奈哌齐（ｄｏｎｅｐｅｚｉｌ，Ａｒｉｃｅｐｔ）形成竞争。据统计至２０００年１０月
Novarits cholinesterase inhibitor rivastigmine (Exelon) was marketed in the United States in late June 2000, expanding the Alzheimer’s drug treatment market and competing with Eperyo (Picea), an Eisai / Pfizer company. According to statistics until October 2000